Is there a survival difference between single station and multi-station N2 disease in operated non-small cell lung cancer patients?

Akçam, Tevfik İlker; Kaya, Şeyda Örs; Akçay, Onur; Samancılar, Özgür; Ceylan, Kenan Can; Sevinç, Serpil; Ünsal, Şaban

doi:10.1016/j.ctrc.2015.09.007

Cited by 2 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The stage III cohort generally consisted of multiple histological types with a majority of squamous cell carcinoma and adenocarcinoma patients, except for 2 studies which consisted solely of adenocarcinoma [17] or squamous cell carcinoma [51] patients and 10 studies in which histological type was not reported specifically for stage III patients [14,31,33,35,39,74] or at all [20,50,64,70]. Stage III patients were treated exclusively with chemotherapy and/or radiotherapy in 39 studies [11-13,15,18,20,21,31,32,34-36,41,45,47,48 ,51,53-56,58-60,64,65,67,70-72,74,76,77,80-85], while surgery was an option in 25 publications [14,16,17,33,[37][38][39][40][42][43][44]46,49,50,52,57,[61][62][63]66,68,73,75,78,79]. A single study did not report treatment modalities [69].…”

Section: Resultsmentioning

confidence: 99%

“…Finally, 5 studies with alternative or unspecified comparisons reported T-stage to not be statistically significant for OS in univariate and 1 out of 2 multivariable analyses [46,50,75,79,84]. Four of these reported surgery as a possible treatment modality, and, as 2 consisted only of stage IIIA patients, their relevance was lower.…”

Section: Resultsmentioning

confidence: 99%

“…Prognostic factors that could not be classified as size, nodal, or texture-related, were classified as other CT-related prognostic factors (Table 2). These included 8 unique factors: Atelectasis/ Obstructive pneumonitis [20,67], Location [18,34,42,48,49,52,62,63,71,72,75,78], Cavitary wall thickness [17], Cavitation [33,44,51], Interstitial lung abnormalities [55], Great vessel invasion [82], Pit fall sign [14], and Pleural effusion [39].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Laar

Amsterdam

Lindert

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

Introduction: Prognosis prediction is central in treatment decision making and quality of life for nonsmall cell lung cancer (NSCLC) patients. However, conventional computed tomography (CT) related prognostic factors may not apply to the challenging stage III NSCLC group. The aim of this systematic review was therefore to identify and evaluate CT-related prognostic factors for overall survival (OS) of stage III NSCLC. Methods: The Medline, Embase, and Cochrane electronic databases were searched. After study selection, risk of bias was estimated for the included studies. Meta-analysis of univariate results was performed when sufficient data were available. Results: 1595 of the 11,996 retrieved records were selected for full text review, leading to inclusion of 65 studies that reported data of 144,513 stage III NSCLC patients andcompromising 26 unique CT-related prognostic factors. Relevance and validity varied substantially, few studies had low relevance and validity. Only four studies evaluated the added value of new prognostic factors compared with recognized clinical factors. Included studies suggested gross tumor volume (meta-analysis: HR = 1.22, 95%CI: 1.05-1.42), tumor diameter, nodal volume, and pleural effusion, are prognostic in patients treated with chemoradiation. Clinical T-stage and location (right/left) were likely not prognostic within stage III NSCLC. Inconclusive are several radiomic features, tumor volume, atelectasis, location (pulmonary lobes, central/peripheral), interstitial lung abnormalities, great vessel invasion, pit-fall sign, and cavitation. Conclusions: Tumor-size and nodal size-related factors are prognostic for OS in stage III NSCLC. Future studies should carefully report study characteristics and contrast factors with guideline recognized factors to improve evidence evaluation and validation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Laar

Amsterdam

Lindert

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Approximately 85% of lung cancers are non-small cell lung cancer (NSCLC). The most important parameters that determine treatment and survival in this group are the stage of the disease and metastases in the lymph nodes [1,2]. The degree of lymphogenous metastasis of NSCLC not only affects the prognosis of patients, but also largely determines the optimal treatment tactics [1].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, at stage pN 0-1 the first and main stage of treatment is surgery, at pN 3 -chemotherapy and radiotherapy. The tactics of treating patients with pN 2 have not yet been fully determined and are the subject of active discussion in the literature [3,4]. Recent practice guidelines consider chemotherapy and radiation therapy to treat patients with pN 2 , and do not recommend isolated or primary surgery [5].…”

Section: Introductionmentioning

confidence: 99%

Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva

2021

View full text Add to dashboard Cite

The aim of this study was to compare overall survival (OS) rates at different pN stages of NSCLC depending on tumor characteristics and to assess the applicability of saliva biochemical markers as prognostic signs. The study included 239 patients with NSCLC (pN0-120, pN1-51, pN2-68). Saliva was analyzed for 34 biochemical indicators before the start of treatment. For pN0, the tumor size does not have a prognostic effect, but the histological type should be taken into account. For pN1 and pN2, long-term results are significantly worse in squamous cell cancer with a large tumor size. A larger volume of surgical treatment reduces the differences between OS. The statistically significant factors of an unfavorable prognosis at pN0 are the lactate dehydrogenase activity <1294 U/L and the level of diene conjugates >3.97 c.u. (HR = 3.48, 95% CI 1.21–9.85, p = 0.01541); at pN1, the content of imidazole compounds >0.296 mmol/L (HR = 6.75, 95% CI 1.28–34.57, p = 0.00822); at pN2 levels of protein <0.583 g/L and Schiff bases >0.602 c.u., as well as protein >0.583 g/L and Schiff bases <0.602 c.u. (HR = 2.07, 95% CI 1.47–8.93, p = 0.04351). Using salivary biochemical indicators, it is possible to carry out stratification into prognostic groups depending on the lymph node metastasis.

show abstract

Is there a survival difference between single station and multi-station N2 disease in operated non-small cell lung cancer patients?

Cited by 2 publications

References 23 publications

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva

Contact Info

Product

Resources

About